

# **AVENIO Oncology Analysis Software**

Exceptional performance, minimal effort



Analysis Customer_Anal	lysis Ani	alysis complet Apr 2018 13:3	ted date 80:25 PDT	SU Ros	bmitted by salind	Soft 2.0.1 BCL mour	ware version 0 folder location ht:bcl1/180417_NE	501362_0 A
Analysis name Customer_Analysis	Tota	analysis time	e (hh:mm)	Run Tiss	sue		SNVs	Indels
Analysis ID AF-dDxG1vFtCvp9b9nVa8jC2	2 02:0.	2 todala	CNVs	Fusio	ons	Sample ID Panel		0
Sample ID	SNVs	Indels			>	xeno-spike1_2 Targeted - A-A2	68	v
paner xeno.spike1_1	37	0	2	0	-	ninge mike2 2	7	1
Targeted - A-A1	-	-	0	0	>	Targeted - A-B2	-	
xeno.spike2_1 Targeted - A-B1	71	4	-	-	1	xeno-spike3_2	▲ 57	1
1	3	1	0	0	1	Targeted - A-C2		
Targeted - A-C1	-							

### AVENIO Oncology Analysis Software



The AVENIO Oncology Analysis Software processes sequencing data from plasma and tissue samples run using the AVENIO ctDNA Analysis Kits V2 and AVENIO Tumor Tissue Analysis Kits V2.

The interface guides users confidently through the post-sequencing workflow. Intelligent bioinformatics with advanced proprietary algorithms and error suppression strategies deliver comprehensive results with proven accuracy and reproducibility.<sup>1,2</sup>

Powerful and intuitive, the AVENIO Oncology Analysis Software offers simplicity, efficiency and accuracy.

For Research Use Only. Not for use in diagnostic procedures.





### Set up and run the analysis with ease

The AVENIO Oncology Analysis Software requires minimal expertise to set up and run an analysis. This allows laboratory and bioinformatics professionals to focus more of their time on the findings and insights, and less on managing information systems.

Intuitive user interface:

- Select plasma or tissue
- Supports two user types (Admin, Lab User)
- Provides real-time tracking of analysis status
- Enables filtering, custom annotation, and analytical concordance reporting between tissue and plasma
- Provides reports in PDF format, as well as variant results in VCF and BAM file formats.

With its ability to process approximately 800 million reads in less than a day, the AVENIO Oncology Analysis Software can be set up to run in the evening, delivering results ready for review in the morning.



# Detect all four mutation classes in a single DNA workflow

The software's bioinformatic algorithms and checkpoints have been optimized to enable accurate variant calls across all four mutation classes.<sup>1</sup>

## Detect low frequency alleles with exceptional sensitivity and specificity

The AVENIO Oncology Analysis Software employs integrated digital error suppression (iDES) strategies in the ctDNA workflow, combining molecular barcodes with in silico error suppression techniques. This proprietary method enables detection of low frequency alleles down to 0.1% with exceptional sensitivity and specificity.<sup>1,2</sup> The tumor tissue workflow employs enzymatic error suppression and molecular barcodes for accurate detection of all four mutation classes from DNA only.

#### **Performance metrics**<sup>1</sup>

AVENIO ctDNA Ana	alysis Kits \	/2						
Mutont Allolo Frequency/	S	NVs	In	dels	Fu	sions	CN	/s**
Copy Number	0.9	50⁄0*	1.0	0⁄0*	1.	0%		
AVENIO Tissue Kit V2	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV
Targeted	>99%	>99%	>99%	>99%	>99%	>99%	SD	>99%
Expanded	>99%	>95%	>99%	>99%	>99%	>99%	SD	>99%
Surveillance	>99%	>99%	>99%	>99%	>99%	>99%	SD	>99%

SD: Sample dependent; \* Detects variants down to 0.1%; \*\*Can detect ERBB2, EGFR and MET CNVs. Performance dependent on input sample type and input concentration(10 ng - 50 ng per reaction). Performance samples: Seraseq ctDNA Complete Mutation Mixes (SeraCare), healthy donor cfDNA. Sensitivity and Positive Predictive Value (PPV) metrics based on observed product performance. Sensitivity and PPV performance reported per variant. Sensitivity was determined using commercially available reference samples containing verified mutations at the stated allele frequencies. SNV performance data based on hotspot calls. The AVENIO ctDNA Analysis Kit V2 can achieve.>99.99% per base specificity across each of the panels. Stated performance requires at least 40 million reads per sample for all AVENIO ctDNA Panels V2. Sequencing performed on an Illumina<sup>®</sup> NextSeq<sup>TM</sup> 500/550/550Dx instrument.

AVENIO Tumor Tissue Analysis Kits V2

	S	NVs	In	dels	Fu	sions	CNVs		
Mutant Allele Frequency/ Copy Number	5	%	5	i%	5	0⁄0			
AVENIO ctDNA Kit V2	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	
Targeted	>99%	>99%	>99%	>98%	>99%	>99%	SD	>99%	
Expanded	>99%	>99%	>99%	>99%	>99%	>99%	SD	>99%	
Surveillance	>99%	>99%	>99%	>99%	>99%	>99%	SD	>99%	

SD: Sample dependent; Samples: FFPE tissue curls/ sections, DNA input: ≥20 ng of FFPET DNA, total DNA amount for each sample determined by input QC DNA. Sensitivity and Positive Predictive Value (PPV) metrics based on observed product performance. Sensitivity and PPV performance reported per variant. Sensitivity was determined using commercially available reference samples containing verified mutations at the stated allele frequencies. SNV performance is panel wide. Indel, Fusion and CNV performance based on whitelist variants. AVENIO Tumor Tissue Analysis Kits V2 achieve >99.99% per base specificity across each of the panels. Stated performance requires at least 20 million reads per sample for Targeted, Expanded and Surveillance Kits V2. Sequencing performed on an Illumina<sup>®</sup> NextSeq <sup>™</sup> 500/550/550Dx instrument.

4

ysis itomer_Ana	Sample Ilysis > xeno.:	spike1_1									24 Apr 2018 11:27:59 PD
ripie () so.spike1_1		Targeted		Description for the second sec	N	wFilte				A-A1	ime
P DNA Q+		101.31mg		Distory pression Tissue_cates arrest.	special						
Results L	oci of interest	Reports	Output files								
Select filter o	et or report:	N	ewFilter						•		Show report
SNVs an	d indels (37)	CNVs and	fusions (2)								39 total variants
Incolory	A				COSANC TCOA		EAC BOR			E 1998 Genteries Loss of interest	Dutation
Gene *	Veriana 2		Variant description			Arrest	adares .				
ALK	p.Oly845Cly		Synonymous variant		91.30%	•		٠			
APC	p.Arg348Arg		Synchymous karkan		1.55%	٠	٠	٠			
APC	р. Тут466 Тут		Synonymous variant		\$7.62%	٠		٠	÷		
APC	p.Thr1493Thr		Synómymous xarian		100.00%	•	•	٠			
APC	p.Pro1960Pro		Synonymous versard		100.00%	٠		٠			
BRAF	p.Gly643Gly		Synónymious varian		10.04%	٠	٠	٠	÷		
IRCAT	p Lyst 183Arg		Missense variant		7.26%	•		٠			
BRCA1	p.Pro871Lee		Missense variant		5.29%	•	٠	٠			
BRCAT	p.Sar694Ser		Synonymous variant		10.11%				+		
BRCA2	p.Asn372Hs		Missense variant		4175	٠	٠	٠			
1-10 of 37 R	insuits .										2 5 4 + ++

ISANGLE ID HD769_InvetSrg ISANGLE TYPE Tissue Isangle Provide	ti Pi ri mC	AUAC YEAR ADDUPLEY 21 Apr 2018 00:0 mont. AVENO FFPET Salary 8 Provide ro	navuse 3,06 PDT Targeted Panet Alt
AA1 BBACTE		A DATE OF BASE FO	CALACTION
SAME EMETHICS		ay Jan 2016	
NUMBER OF FRANKS	19 M	PERIZAT SAPYTO HEADIN	18.42%
DEPTH	11793.0 (6482.4 - 23889.3) Messe (01 - 60 percentine)	-and breni	3739.0 (2425.0 - 7742.0) Moter III - Old secondine
TEMOR BATE	7.824-05	ING MEAN TRATE	70.67%
TRADIENT	190 (107 - 375) Mailler (Mr 80) percentions		
Coverage Uni	formity	Allele Fraction	Distribution
	r fase datin telan Selan Telana atalan	mandorme at	

### **Call mutations with confidence**

Five leading oncology databases, a curated loci of interest list and a customizable annotation database are integrated into the AVENIO Oncology Analysis Software. This allows quick and easy access to trusted public resources for cross-referencing and verification of results:

- COSMIC
- TCGA
- ExAC
- dbSNP
- 1000 Genomes

# These annotation databases can help users call mutations with increased confidence.

### **Control quality across the workflow**

The AVENIO Oncology Analysis Software provides a sequencing quality report with key metrics such as sequencing depth, number of reads, on-target rate, coverage uniformity, and error rate to confirm quality at different stages in the workflow.

#### For Research Use Only. Not for use in diagnostic procedures.

1. Data on file with Roche.

Data of the with house.
Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.

Published by:

#### **Roche Sequencing and Life Science** 9115 Hague Road Indianapolis, IN 46256

#### go.roche.com/assays

AVENIO is a trademark of Roche. NEXT SEQ is a trademark of Illumina. All other product names and trademarks are the property of their respective owners.